Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into Agios Pharmaceuticals Phase 2a study of AG-946 for treatment of adult patients with Anemia due to Lower-Risk Myelodysplastic Syndromes (LR-MDS).

Ticker(s): AGIO

Who's the expert?

Institution: Stanford Medical Center

Professor of Medicine (Hematology), Emeritus and Director of the Stanford Myelodysplastic Syndromes (MDS) Center.
Manages roughly 150 patients with anemia due to LR-MDS
Clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies

Interview Goal

This interview will focus on the clinical proof-of-concept achieved in the Phase 2a portion of the investigational pyruvate kinase (PK) activator AG-946 as a potential treatment for anemia in adults with lower-risk myelodysplastic syndromes (LR-MDS)

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.